We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 138

Sidley Austin LLP global pricing newsletter - volume three 2014

  • Sidley Austin LLP
  • -
  • Brazil, Canada, China, European Union, France, Germany, India, United Kingdom, USA
  • -
  • April 15 2014

On October 21, 2013, Brazil’s National Agency of Supplemental Health enacted Normative Resolution 388, which mandated that all private healthcare

The COPAXONE story in the U.S. and India: a further update

  • Michael Best & Friedrich LLP
  • -
  • India, USA
  • -
  • April 9 2014

As an update to our March 5th and April 4th postings, The Copaxone Story in the U.S. and India and The Copaxone Story in the U.S. and India: An

The COPAXONE story in the U.S. and India: an update

  • Michael Best & Friedrich LLP
  • -
  • India, USA
  • -
  • April 4 2014

As an update to our March 5th posting, The Copaxone Story in the U.S. and India, the U.S. Supreme Court (Supreme Court) this week granted Teva

Draft guidelines for examining pharma patent applications

  • Lakshmikumaran & Sridharan
  • -
  • India
  • -
  • March 19 2014

On February 28 2014 the Indian Patent Office issued draft guidelines for the examination of patent applications in the pharmaceuticals field

The Galderma case gaining perspective for India

  • RK Dewan & Co
  • -
  • India, USA
  • -
  • March 18 2014

Galderma, a Swiss pharmaceutical company majoring in dermatological preparations, has been doing the rounds in the global intellectual property

The COPAXONE story in the U.S. and India

  • Michael Best & Friedrich LLP
  • -
  • India, USA
  • -
  • March 5 2014

Teva Pharmaceutical Industries Ltd. (Teva) markets Copaxone (a 20 milligram daily injection) for the treatment of multiple sclerosis. The active

IPAB quibble Indian Patent Office on rejecting Schering’s crystalline form patent of vorapaxar

  • Singh & Associates
  • -
  • India
  • -
  • March 1 2014

The importance of following due process when reviewing patent applications was reinforced in the recent Intellectual Property Appellate Board' (IPAB

Concurrent delays in construction work

  • Singh & Associates
  • -
  • India, United Kingdom
  • -
  • March 1 2014

"Time is money" is a settled statement in the construction industry, which drives and motivates every person engaged in an industry. The financial

U.S. Trade Rep launches WTO action against India

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • February 13 2014

U.S. Trade Representative Michael Froman has announced that the United States has requested dispute settlement consultations with India before the

Review of existing policy for FDI in pharma sector

  • Singh & Associates
  • -
  • India
  • -
  • February 7 2014

According to Circular 1 of 2013 - consolidated FDI Policy, relating to FDI in Pharmaceuticals Sector, 100 FDI is allowed for green field and